PharmaSphere: North American Market Access Strategy
GlobalData’s PharmaSphere: North American Market Access Strategy report provides a strategic analysis of the pharmaceutical market landscape in this geographic region, and the impact of the current and emerging market access strategies that the pharmaceutical industry is using for its for new and existing drugs. It discusses the regulatory requirements for pharmaceutical products in North American, key health insurance trends, recent government healthcare reforms, and general industry trends. It also describes the macroeconomic factors that impact the commercialization of new pharmaceutical products. Furthermore, it includes a geographic segmentation of the various markets in North America, including the US, Canada, and Mexico, providing an in-depth analysis of these markets’ regulatory frameworks, healthcare systems, health insurance markets, key domestic players, and strategic outlook.
Key Questions Answered
What are the main factors influencing market access in North America?
How do demographic trends impact market access in Canada and Mexico?
What are the important elements of the healthcare systems in the US, Canada, and Mexico?
How important is health technology assessment (HTA)? What are the key processes leading up to a successful HTA in North America?
What are the different pricing and reimbursement procedures adopted by regulators in North America?
How has recent healthcare reform legislation changed market access considerations from the perspective of regulators and pharmaceutical companies?
How have cost-containment pressures impacted the commercialization of new pharmaceutical products?
Reasons to buy
Identify the key decision makers in various countries in the North American region, including the US, Canada, and Mexico
Understand the key causes, concerns, drivers, and trends that characterize the market access process
Analyze the impact of recent healthcare reform legislation on market access procedures
Identify the key factors in the market access process, such as pricing, reimbursement, co-payments, discounts, and pharma economic guidelines
Understand the impact of macroeconomic factors, such as healthcare expenditures, foreign direct investment (FDI), and population demographics on the market access process
North American Pharmaceutical Market Focus Shifting from Prescriber to Payer, says GlobalData
Following the global economic recession and a slower-than-anticipated recovery, cost-containment measures are shifting the decision-making focus of North America’s pharmaceutical market from the prescriber to the payer, says research and consulting firm GlobalData.
The company’s latest report* states that the global pharmaceutical industry is currently being confronted with intensified obstacles along the path to new product commercialization, with pricing and reimbursement hurdles particularly challenging for the North American market.
According to Adam Dion, MS, GlobalData’s Healthcare Industry Analyst, as overall healthcare spending has slowed during the recession, new pharmaceutical products and medical technologies have received increased attention regarding their potential cost savings.
Dion comments: “While the US population is largely covered through private health insurance, public sector coverage now includes third-party administrators, dispensers, and others, further complicating the situation.
“At the other end of the spectrum is Canada, where the single-payer system has meant sweeping cost-containment measures and a stricter pricing and reimbursement policy, which is a challenge for pharmaceutical companies.”
The analyst adds that as market access regulations are becoming more stringent, product commercialization strategies will be helped by mapping a successful launch sequence of countries that have not only good domestic drug demand, but also the right pricing and reimbursement conditions.
However, while there have been continued efforts to lower spending on prescription drugs, on which the US spends approximately one tenth of its healthcare budget, the number of products with an annual cost totaling at least $100,000 has increased markedly over the past five years.
Dion continues: “The rise in premium-priced drugs has been most notable in the oncology and infectious diseases segments, particularly Amgen’s leukemia drug Blincyto, and Gilead’s hepatitis C virus treatments Sovaldi and Harvoni.
“Despite discounts provided by manufacturers, the demand for innovative drug treatments in areas with high unmet need means that the continued influx of such therapies is likely to impact costs heavily for both insurers and patients,” the analyst concludes.
*PharmaSphere: North American Market Access Strategy
This report provides a strategic analysis of the pharmaceutical market landscape in North America, and the impact of the current and emerging market access strategies used by the pharmaceutical industry for new and existing drugs. It discusses the regulatory requirements, key health insurance trends, recent government healthcare reforms, and general industry trends.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.